Abstract: Objective To evaluate the value of serum HE4 content testing on diagnosis for ovarian cancer. Methods We searched for 16 articles through all literature from 2000 to 2010 about testing of serum HE4 content in patients with ovarian cancer to be searched systematically from VIP, Qing Hua Tong Fang, MEDLINE, NCBI PubMed and EMBASE database. Results were combined with random effects models. RevMan 4.2.10 software was applied to process data. Results The sensitivity of serum HE4 in human ovarian carcinoma was 73%, 95% confidence interval, 0.68 to 0.82; the specificity was 0.95, 95% confidence interval, 0.93 to 0.98; the positive predictive was 0.89, 95% confidence interval, 0.83 to 0.95; the negative predictive was 0.85, 95% confidence interval, 0.80 to 0.90. Conclusion This meta-analysis confirms that HE4 as ovarian tumor biomarkers has some value on diagnosis ovarian cancer.